Koers Apricus Biosciences Inc Nasdaq
Aandelen
US03832V3078
Biotechnologie & Medisch Onderzoek
Omzet 2022 | - | Omzet 2023 | 2,2 2,04 | Marktkapitalisatie | 13,61 mln. 12,63 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -73 mln. -67,71 mln. | Nettowinst (verlies) 2023 | -37 mln. -34,32 mln. | EV/omzet 2022 | - |
Nettoschuld 2022 | 4,59 mln. 4,26 mln. | Nettoschuld 2023 | 11,23 mln. 10,42 mln. | EV/omzet 2023 | 11.278.477 x |
K/w-verhouding 2022 |
-0,98
x | K/w-verhouding 2023 |
-0,18
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 98,35% |
Recentste transcriptie over Apricus Biosciences Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Raj Mehra
CEO | Chief Executive Officer | 64 | 01-01-87 |
Director of Finance/CFO | 52 | 01-01-19 | |
Karen Fusaro
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 77 | 01-09-21 | |
Richard Pascoe
CHM | Chairman | 60 | 01-03-13 |
Daniel O'Connor
BRD | Director/Board Member | 59 | 01-01-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,64% | 105 mld. | |
-0,90% | 104 mld. | |
+5,44% | 22,94 mld. | |
-12,25% | 22,34 mld. | |
-6,31% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-8,69% | 16,96 mld. | |
+7,59% | 14,16 mld. | |
+38,96% | 12,63 mld. |